#RNL2023:Kevin Deane: Anti-CCP positive leads to a 20-30% risk for articular clinical RA within 3-5 years https://t.co/U

Tweet Author

Tweet Content

#RNL2023:Kevin Deane: Anti-CCP positive leads to a 20-30% risk for articular clinical RA within 3-5 years https://t.co/UvXfC2iIEp https://t.co/zBoMiyy056

Links

https://bit.ly/3JK6nn8

EULAR has published the 2022 update on recommendations for the management of antineutrophil cytoplasmic antibody (ANCA)-

Tweet Author

RheumNow

Tweet Content

EULAR has published the 2022 update on recommendations for the management of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV). https://t.co/0fXUVv0sCR https://t.co/fT6iAOPOpc

Links

https://bit.ly/3Kagzqw

RT @LupusResearch: LRA announces the 2023 recipients of the Lupus Innovation Award during #NationalKidneyMonth as three

Tweet Author

LupusResearch

Tweet Content

LRA announces the 2023 recipients of the Lupus Innovation Award during #NationalKidneyMonth as three of this year’s seven award recipients are studying issues that come with this too-common complication. 🧵1of2 https://t.co/VZL9qJu9kF

Night Splinting for Carpal Tunnel (3.24.2023)

24 March 2023

Night Splinting for Carpal Tunnel (3.24.2023)

Dr. Jack Cush reviews the news and journal articles from the past 2 weeks on RheumNow.com. This week reviews clinical associations with SS-A, a new biomarker for SSc-ILD and cancer screening for myositis patients.

29 pts w/ PsA Sine Psoriasis: 16F/13M, mean age 45 yrs w/ PsA ~6.2 yrs. 54% had 1st-degree relatives with PsA. 66% had DIP arthritis, 39% polyarticular, 36% oligoarticular, 25% were axial. Nail findings seen in 89%, enthesitis 59%, dactylitis 62% https://t.co/FPAqosYr9C

Updated AAV Treatment Recommendations AAV is a multi-organ disease, which can be complex and may vary from person to p

Tweet Author

RheumNow

Tweet Content

Updated AAV Treatment Recommendations AAV is a multi-organ disease, which can be complex and may vary from person to person. Types of AAV include GPA, microscopic polyangiitis (MPA), and eosinophilic granulomatosis with polyangiitis (EGPA). https://t.co/YCNGYZfSr1 https://t.co/MFs9ykm4fb

Links

https://bit.ly/3z4eBl1

Our old friend, hydroxychloroquine Dr.Arnaud ( @Lupusreference ) took the time to review one of our oldest therapies:

Tweet Author

RheumNow

Tweet Content

Our old friend, hydroxychloroquine Dr.Arnaud ( @Lupusreference ) took the time to review one of our oldest therapies: hydroxychloroquine. He outlined how the anti-malarial medication has efficacy and widespread usage in lupus. https://t.co/hKFLg1sogJ https://t.co/OxnbwpWygF

Links

https://bit.ly/40b4Ptp

#RNL2023 Dr. Stanley Cohen: possible adverse effects of JAKi -Herpes zoster, other infections -Malignancy -Occasional c

Tweet Author

RheumNow

Tweet Content

#RNL2023 Dr. Stanley Cohen: possible adverse effects of JAKi -Herpes zoster, other infections -Malignancy -Occasional cytopenias -LFTs (with DMARDs) -Incr Cr or CPK -Acne -Incr lipids -GI perf -VTE Which do you counsel with your patients? https://t.co/8bEEC6gt5Z https://t.co/Toy2DxnC4S

Links

https://bit.ly/3yWHKyB

Treat to target approach in PsA Systematic rev: 12-43% pts achieved target of very low disease activity or remission Pts

Tweet Author

RheumNow

Tweet Content

Treat to target approach in PsA Systematic rev: 12-43% pts achieved target of very low disease activity or remission Pts and docs agree: remission is primary goal, but Low disease activity is acceptable alternative @DrLauraCoates at #RNL2023 https://t.co/XyXBAn82F1 https://t.co/W0nVdq6urq

Links

https://bit.ly/3LLlEXj

#RNL2023: Kevin Deane: Anti-CCP positive leads to a 20-30% risk for articular clinical RA within 3-5 years @RheumNow htt

Tweet Author

RheumNow

Tweet Content

#RNL2023: Kevin Deane: Anti-CCP positive leads to a 20-30% risk for articular clinical RA within 3-5 years @RheumNow https://t.co/vPflDm22b2 https://t.co/7Al9I3Eidu

Links

https://bit.ly/42xrKAD

Topics

#RNL2023:Kevin Deane: Anti-CCP positive leads to a 20-30% risk for articular clinical RA within 3-5 years https://t.co/U

EULAR has published the 2022 update on recommendations for the management of antineutrophil cytoplasmic antibody (ANCA)-

RT @LupusResearch: LRA announces the 2023 recipients of the Lupus Innovation Award during #NationalKidneyMonth as three

Night Splinting for Carpal Tunnel (3.24.2023)

Updated AAV Treatment Recommendations AAV is a multi-organ disease, which can be complex and may vary from person to p

Our old friend, hydroxychloroquine Dr.Arnaud ( @Lupusreference ) took the time to review one of our oldest therapies:

#RNL2023 Dr. Stanley Cohen: possible adverse effects of JAKi -Herpes zoster, other infections -Malignancy -Occasional c

Treat to target approach in PsA Systematic rev: 12-43% pts achieved target of very low disease activity or remission Pts

#RNL2023: Kevin Deane: Anti-CCP positive leads to a 20-30% risk for articular clinical RA within 3-5 years @RheumNow htt

Do you get our email newsletter?